DiabetesURICANCT02671656
Study of the Reliability of a Device (HumanSens Plus) Allowing Immediate Measurement Uric Acid in the Blood Obtained by Finger Tip Puncture.
An observational study of Diabetes, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Lowering the level of uric acid in the serum under 6mg/dL on the long term is a key factor of gout management success. Monitoring of uricemia in gout patients is therefore important and is presently done in the laboratory on serum samples obtained after venous puncture. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes
- What is being tested?
- Uricemia
- Type of treatment
- Medical device
- How many people
- 0 participants
- Where
- 1 siteFrance
- Study dates
- Mar 2016to Apr 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with Diabetes
Who may be able to join
- Patients seen in the diabetology day hospital
- Patients aged at least 18 years-old
- French-speaking patients
- Patients able to understand the study and the information form
Who cannot join
- Patients unable to understand the aim of study aind the information sheet
- Patients not affiliated to a social security scheme (beneficiary or assignee)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Reliability Assessment of the HumaSens Plus Measurement of Uricemia in Capillary Blood
Lowering the level of uric acid in the serum under 6mg/dL on the long term is a key factor of gout management success. Monitoring of uricemia in gout patients is therefore important and is presently done in the laboratory on serum samples obtained after venous puncture. This study aims at assessing the reliability of immediate uricemia measurement in a blood sample obtained by a mere fingertip puncture, by the HumaSensplus system, which is commercially available in the EU. Results obtained by the Humasens device will be compared to those of the standard measurement technique in serum and with a reference technique (liquid chromatography and mass spectroscopy). If the device appears reliable, it will allow self-measurement of uric acid by the gouty patient, in a similar way as diabetic patients measure their glycaemia following a fingertip puncture. This should improve patient monitoring and management effects.
Read the detailed description
The aim of this study is
- to assess the validity of the capillary measure of uric acid level by the HumaSens plus system by comparing the measurement of total blood uric acid level by the HumaSens plus system with the routine measurement of serum uric acid by a standard and validated automated colorimetric method (primary objective).
- to look for a systematic bias and confounding factors (secondary objectives)
Methods
Design : This is a mono-centric prospective study. Patients will be recruited from the diabetology day hospital of hospital Lariboisière, Paris
Data collection : For each patient included at the Lariboisière Diabetology day hospital and included in this study, serum uric acid levels will be measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods, as presently routinely done and by liquid chromatography coupled with mass spectroscopy. In, addition, uric acid levels will also be simultaneously measured from capillary blood with the HumaSensplus system.
Hematocrit, glucose, cholesterol and triglycerides will be measured as well from venous blood samples and taken medications will be listed.
Planned analysis :
Planned sample size:
To obtain an estimated intraclass correlation of 0,800, with a two-sided 95% confidence interval with a width of 0,100, if the uric acid level is measured twice for each subject, we calculated that we needed a random sample of 204 subjects.
Statistical analyses:
Primary aim This study aims at studying the reliability of measurements of acid uric level by HumanSensplus against laboratory and measurements by liquid chromatography coupled with mass spectroscopy on serum from venous blood. There is no structure to the replicate measurements in the sense that nothing ties the first or second measurement on one patient to the first or second on another. The study thus conforms to a one-way random effect model. The data will be analyzed using a one-way random-effects ANOVA model.
The estimator of the intraclass correlation coefficient will be
With BMS=between-subject mean square, WMS=within-subject mean square and k0 = number of replicates. In this study k0=2.
The intraclass correlation coefficient will be calculated and the two-sided 95%CI will be provided for each comparison.
In addition differences between measurements will be plotted against mean of measurements in accordance with Bland and Altman.
Secondary aims The search for systematic bias and effect of confounding factors (hematocrit, glycemia, lipid concentrations and concomitant medications) will use different models of multiple regression
Logistic aspects
Ethical aspects:
Agreement will be sought from the local Ethics committee. All patients will be fully informed and will be provided with an information form. The data will be entered into an excel database and will be analysed anonymously. Fingertip glycaemia is presently systematically obtained in all these day hospital patients, and the addition of fingertip uricaemia in view of substituting this measurement to the systematic serum uric acid measurement presently done from a venous system in the biochemistry laboratory can be considered as a mere attempt to improve routine patient care.
Inclusion procedure:
The study will target 200 patients seen in diabetology day hospitalisation and fulfilling the inclusion criteria. As 15 patients are seen in the diabetology day hospitalisation ward every day, we estimate that the necessary patients sample size could be obtained within 6 weeks.
- Conditions
- Diabetes
- Being tested
- Uricemia
- Keywords
- Uricemia
- Medical subject headings
- Diabetes Mellitus, Hyperuricemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
UricemiaDevice
serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
What is being measured
The primary outcome is the main question the study is designed to answer.
Uricemia
Comparison the measurement of uric acid level by the HumaSensplus system with the routine measurement of uric acid by the automated colorimetric uricase method (Abbot), and with a reference method: liquid chromatography coupled with mass spectroscopy.
This will be done once for every patient.
Measured: Day0
Secondary outcomes (2)
Uricemia on capillary blood vs on serum
Search for a systematic bias (the HumaSens measurement is on capillary blood whereas the other techniques are done on serum)
Measured: Day0
Haematocrit, glucose and lipid levels, medications
Search for confounding factors (haematocrit, glucose and lipid levels, medications) which may affect the results of the HumaSens measurement
Measured: Day0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2016 (estimated)
- Study startMar 2016
- Primary completionApr 2016 (estimated)
- Study completionApr 2016 (estimated)
Why it stopped: faisability
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Collaborators
- ART-Viggo, Rheumatology department, Lariboisière Hospital, Paris, France
- Responsible party
- Sponsor
- Investigators
- Thomas BARDIN, MD, PhD, Principal investigator, Assistance Publique - Hôpitaux de Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02671656
- Sponsor's protocol ID
- UC1501
- Acronym
- URICA
- Status last verified
- Jun 2021
- First submitted
- 29 Jan 2016
- Last updated
- 18 Jun 2021
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reliability Assessment of the HumaSens Plus Measurement of Uricemia in Capillary Blood
- ClinicalTrials.gov ID
- NCT02671656
- Acronym / sponsor ID
- URICA / UC1501
- Conditions
- Diabetes
- Keywords
- Uricemia
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: faisability
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- ART-Viggo, Rheumatology department, Lariboisière Hospital, Paris, France
- Study start
- Mar 2016
- Primary completion
- Apr 2016 (estimated)
- Study completion
- Apr 2016 (estimated)
- First posted
- 2 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lowering the level of uric acid in the serum under 6mg/dL on the long term is a key factor of gout management success. Monitoring of uricemia in gout patients is therefore important and is presently done in the laboratory on serum samples obtained after venous puncture. This study aims at assessing the reliability of immediate uricemia measurement in a blood sample obtained by a mere fingertip puncture, by the HumaSensplus system, which is commercially available in the EU. Results obtained by the Humasens device will be compared to those of the standard measurement technique in serum and with a reference technique (liquid chromatography and mass spectroscopy). If the device appears reliable, it will allow self-measurement of uric acid by the gouty patient, in a similar way as diabetic patients measure their glycaemia following a fingertip puncture. This should improve patient monitoring and management effects.
Detailed description
The aim of this study is
- to assess the validity of the capillary measure of uric acid level by the HumaSens plus system by comparing the measurement of total blood uric acid level by the HumaSens plus system with the routine measurement of serum uric acid by a standard and validated automated colorimetric method (primary objective).
- to look for a systematic bias and confounding factors (secondary objectives)
Methods
Design : This is a mono-centric prospective study. Patients will be recruited from the diabetology day hospital of hospital Lariboisière, Paris
Data collection : For each patient included at the Lariboisière Diabetology day hospital and included in this study, serum uric acid levels will be measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods, as presently routinely done and by liquid chromatography coupled with mass spectroscopy. In, addition, uric acid levels will also be simultaneously measured from capillary blood with the HumaSensplus system.
Hematocrit, glucose, cholesterol and triglycerides will be measured as well from venous blood samples and taken medications will be listed.
Planned analysis :
Planned sample size:
To obtain an estimated intraclass correlation of 0,800, with a two-sided 95% confidence interval with a width of 0,100, if the uric acid level is measured twice for each subject, we calculated that we needed a random sample of 204 subjects.
Statistical analyses:
Primary aim This study aims at studying the reliability of measurements of acid uric level by HumanSensplus against laboratory and measurements by liquid chromatography coupled with mass spectroscopy on serum from venous blood. There is no structure to the replicate measurements in the sense that nothing ties the first or second measurement on one patient to the first or second on another. The study thus conforms to a one-way random effect model. The data will be analyzed using a one-way random-effects ANOVA model.
The estimator of the intraclass correlation coefficient will be
With BMS=between-subject mean square, WMS=within-subject mean square and k0 = number of replicates. In this study k0=2.
The intraclass correlation coefficient will be calculated and the two-sided 95%CI will be provided for each comparison.
In addition differences between measurements will be plotted against mean of measurements in accordance with Bland and Altman.
Secondary aims The search for systematic bias and effect of confounding factors (hematocrit, glycemia, lipid concentrations and concomitant medications) will use different models of multiple regression
Logistic aspects
Ethical aspects:
Agreement will be sought from the local Ethics committee. All patients will be fully informed and will be provided with an information form. The data will be entered into an excel database and will be analysed anonymously. Fingertip glycaemia is presently systematically obtained in all these day hospital patients, and the addition of fingertip uricaemia in view of substituting this measurement to the systematic serum uric acid measurement presently done from a venous system in the biochemistry laboratory can be considered as a mere attempt to improve routine patient care.
Inclusion procedure:
The study will target 200 patients seen in diabetology day hospitalisation and fulfilling the inclusion criteria. As 15 patients are seen in the diabetology day hospitalisation ward every day, we estimate that the necessary patients sample size could be obtained within 6 weeks.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with Diabetes
Key inclusion criteria (4 listed)
- Patients seen in the diabetology day hospital
- Patients aged at least 18 years-old
- French-speaking patients
- Patients able to understand the study and the information form
Key exclusion criteria (2 listed)
- Patients unable to understand the aim of study aind the information sheet
- Patients not affiliated to a social security scheme (beneficiary or assignee)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Uricemiaserum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods | Device | – |
Primary outcome
Uricemia
Time frame: Day0
Comparison the measurement of uric acid level by the HumaSensplus system with the routine measurement of uric acid by the automated colorimetric uricase method (Abbot), and with a reference method: liquid chromatography coupled with mass spectroscopy. This will be done once for every patient.
2 secondary outcomes
Uricemia on capillary blood vs on serum
Time frame: Day0
Haematocrit, glucose and lipid levels, medications
Time frame: Day0
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2021.
- Individual participant dataSharing planned: No
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas BARDIN, MD, PhD principal investigator
Assistance Publique - Hôpitaux de Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 18 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Uricemia (time frame: Day0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2021.